---
id: ectrims-mcdonald-criteria-2024
title: "2024 Revisions to the McDonald Diagnostic Criteria for Multiple Sclerosis"
short_title: "McDonald MS Criteria 2024"

organization: European Committee for Treatment and Research in Multiple Sclerosis
collaborators:
  - American Academy of Neurology
country: Global (Europe-led)
url: https://www.ectrims.eu/resources/publications/
doi: null
pmid: null
open_access: true

specialty: neurology
guideline_type: clinical-practice
evidence_system: Expert Consensus
conditions:
  - multiple sclerosis
  - MS
  - clinically isolated syndrome
  - radiologically isolated syndrome
tags:
  - MRI
  - central vein sign
  - paramagnetic rim lesions
  - kappa free light chains
  - oligoclonal bands

publication_date: 2024-09-15
previous_version_date: 2017-12-01
status: current
supersedes: mcdonald-2017
superseded_by: null

pdf_path: null
has_pdf: false
last_reviewed: 2025-12-23
---

## Scope
2024 revision to the McDonald diagnostic criteria for multiple sclerosis (MS), providing updated guidance for earlier and more accurate diagnosis using new biomarkers.

## Key Changes

### New Biomarkers
- **Central Vein Sign (CVS)**: The presence of a central vein within MS lesions on MRI is now incorporated as supportive evidence for diagnosis, helping distinguish MS from its mimics.
- **Paramagnetic Rim Lesions (PRL)**: These chronic active lesions, identified on advanced MRI, are recognized as a feature of MS pathology.
- **Kappa Free Light Chains (ÎºFLC)**: Elevated kappa free light chains in CSF are now accepted as an alternative to oligoclonal bands for demonstrating intrathecal immunoglobulin synthesis.

### Optic Nerve
- The **optic nerve** is now recognized as a fifth anatomical location for demonstrating dissemination in space (DIS), in addition to the periventricular, juxtacortical/cortical, infratentorial, and spinal cord regions.

### Application Across Ages
- The revised criteria now apply the same diagnostic framework for **both children and adults**.

### Radiologically Isolated Syndrome (RIS)
- The criteria provide guidance for individuals incidentally found to have MS-like lesions on MRI without clinical symptoms, acknowledging RIS as being on the MS spectrum.

### Goals
- **Earlier Diagnosis**: Enabling clinicians to diagnose MS sooner, which can lead to earlier treatment initiation and potentially better long-term outcomes.
- **Improved Specificity**: The new biomarkers aim to reduce misdiagnosis by differentiating MS from conditions that can mimic it on MRI.
